Anti-Parkinsonian drugs and Neuroleptics Flashcards

1
Q

What are the four main dopaminergic pathways in the brain?

A

Nigrostriatal
Mesolimbic
Mesocortical
Tuberoinfundibular system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Where are each of these pathways found?

A

Nigrostriatal– projecting from the substantia nigra pars compacta to the striatum

Mesolimbic– projecting from the ventral tegmental area to the nucleus accumbens, frontal cortex, limbic cortex and olfactory tubercle

Mesocortical - projecting from ventral tegmental area to diffuse areas of cortex

Tuburoinfundibular system– projecting from the arcuate nucleus in the hypothalamus to the median eminence and pituitary gland

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the roles of these pathways?

A

Nigrostriatal – control of movement
Mesolimbic – involved in emotion
Mesocortical - Emotions and behaviour
Tuburoinfundibular system – regulate prolactin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the two families of dopamine receptors and which receptors fall into each of these families?

A

D1 family – D1 + D5

D2 family – D2, D3 + D4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe dopamine synthesis.

A

Tyrosine is converted by tyrosine hydroxylase to DOPA

DOPA is converted by DOPA decarboxylase to Dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Is Parkinson’s disease more common in males or females?

A

Males – 4:1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What percentage of all cases of Parkinson’s disease is accounted for by familial Parkinson’s disease?

A

8%
SNCA, LRRK2 Mutations cause Early onset (5%)
The rest are idiopathic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the possible causes of idiopathic Parkinson’s disease?

A

Possibly a combination of environmental, oxidative stress, altered protein metabolism and risk genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the cardinal signs of Parkinson’ disease?

A

Resting tremor (pill-rolling tremor)
Rigidity (stiffness – limbs feel weak and heavy)
Bradykinesia (slowness of movement)
Postural abnormality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the presenting symptoms of Parkinson’s disease?

A

Pill-rolling resting tremor
Difficulty with fine movements (micrographia)
Poverty of blinking
Hypomimic face
Monotony of speech and loss of volume of voice
Disorders of posture – flexion of the neck and trunk
Lack of arm swing
Loss of balance – lack of righting reflex, retropulsion
Short steps, shuffling gait

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the initial distribution of symptoms across the body.

A

Unilateral onset
Symptoms spread to both sides
Generally symptoms worsen with some patients becoming severely disabled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are some non-motor symptoms of Parkinson’s disease?

A
Depression 
Pain 
Taste/smell disturbances 
Cognitive decline/dementia 
Autonomic dysfunction (constipation, postural hypotension, urinary frequency/urgency, impotence, increased sweating) 

Autonomic symptoms present before motor symptoms
Neuropsychiatric symptoms present after

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the main area of the brain that is affected by Parkinson’s disease?

A

Substantia nigra

Other brain areas affected: locus coeruleus, dorsal vagus nucleus, nucleus basalis of Mynert

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the neuropathology of Parkinson’s disease.

A

Putamen-projecting pathways degenerate significantly

Lewy bodies (in cell body) and Lewy neurites (in axon) also present – this is probably a defensive mechanism to protect against toxic altered proteins

Abnormal phosphorylated neurofilaments ubiquitin and α-synuclein make them up

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the stages of Parkinson’s disease?

A
1-2 = dorsal motor nucleus of vagus, raphe nucleus, locus coeruleus 
3 = substantia nigra pars compacta 
4 = amygdala, nucleus of Meynert, hippocampus 
5-6 = cingulate cortex, temporal cortex, frontal cortex, parietal cortex, occipital cortex
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the main biochemical change seen in Parkinson’s disease?

A

Marked reduction in the caudate nucleus/putamen dopamine content

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What proportion of dopaminergic neurones of the nigrostriatal dopaminergic pathway must be lost before symptoms occur?

A

80-85% of dopaminergic neurones and 70% of striatal dopamine must be depleted before symptoms appear

There are compensatory mechanisms e.g. neurone overactivity and increase in dopamine receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What other type of drug has to be given with L-DOPA in dopamine replacement therapy and why?

A

Peripheral DOPA decarboxylase inhibitor
This prevents the conversion of L-DOPA to dopamine by peripheral DOPA decarboxylase (this can cause nausea and vomiting)

Also COMT inhibitors – Entacapone and Tolcapone enhance L-DOPA action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

State two different preparation of dopamine replacement therapy.

A
Sinamet = Carbodopa + L-DOPA 
Madopar = Benserazide + L-DOPA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What does L-DOPA treat?

A

Hypokinesia
Tremor
Rigidity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe how the dosage of L-DOPA is changed with continued treatment.

A

It is started low and increased until maximum benefit of drug is achieved without side effects
Effectiveness of L-DOPA declines with time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the acute side effects of L-DOPA?

A
Nausea (prevented by domperidone) 
Hypotension 
Psychological effects (schizophrenia like syndrome with dellusions, hallucinations, confusion, disorientation and nightmares)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the chronic side effects of L-DOPA?

A

Dyskinesias (abnormal movement of limbs and face – can occur within 2 years of treatment – disappear with reduced dose)
Rapid fluctuations in clinical state (off periods may last for minutes to hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Name three dopamine agonists.

A

Bromocriptine (Ergot)
Ropinerol
Pergolide (Ergot)

25
Q

Which receptors do dopamine agonists act on?

A

D2 receptor

26
Q

What are the benefits of dopamine agonists over L-DOPA?

A
Longer duration of action 
Smoother and more sustained response 
Actions independent of dopaminergic neurones 
Incidence of dyskinesias is less 
NOTE: L-DOPA is still the gold standard
27
Q

What are the adverse effects of dopamine agonists?

A

Common – confusion, dizziness, nausea/vomiting, hallucinations
Rare – constipation, headache, dyskinesia

28
Q

What structure used to be present in older dopamine agonists that caused quite serious clinical problems?

A

Ergot ring

This caused problems with heart valves/Cardiac fibrosis

29
Q

What has been the consequence of the removal of ergot rings within dopamine agonists?

A

Development of addictive behaviour e.g. gambling

30
Q

Name two MAO inhibitors.

A

Deprenyl (selegiline)

Rasagiline

31
Q

What are the effects of Deprenyl?

A

Selective for MAO-B (this predominates in dopaminergic areas of CNS)
Does NOT have the peripheral side effects of non-selective MAO inhibitors
Can be given in combination with L-DOPA (reduce dose of L-DOPA by 30-50%)

32
Q

What are the side effects of Deprenyl?

A

RARE
Hypotension
Nausea/vomiting
Confusion and agitation

33
Q

What are the effects of Rasagiline?

A

It has neuroprotective properties by inhibiting apoptosis (promotes anti-apoptosis genes)

NOTE: early clinical trials show this drug might slow down the progression of disease but subsequent studies haven’t been so promising

34
Q

Name two COMT inhibitors.

A

Tolocapone (CNS + PNS)

Entacapone (PNS)

35
Q

What are the effects of COMT inhibition in the CNS?

A

Prevents breakdown of dopamine in the brain

36
Q

What are the effects of COMT inhibition in the peripheral nervous system?

A

Peripheral COMT converts L-DOPA to 3-O-methyl DOPA (3-OMD) 3-OMD competes with L-DOPA for the transport system that transports it across the BBB
COMT inhibitors stop 3-OMD production and hence there is less competition for L-DOPA

Result: REDUCE L-DOPA DOSAGE

37
Q

What are the side effects of COMT inhibitors?

A

Cardiovascular complications

38
Q

What percentage of the general population is affected by schizophrenia?

A

1%

39
Q

What are the positive symptoms of schizophrenia?

A
Positive Symptoms (overt symptoms that should NOT 
be present) 

Hallucinations
Delusions
Disorganised thoughts

40
Q

What are the negative symptoms of schizophrenia?

A

Negative Symptoms (lack of characteristics that SHOULD be present)

Alogia - Reduced speech
Affective flattening -Lack of emotional and facial expression
Anhedonia/Apathy/Avolition

Cognitive deficits

  • Memory
  • Attention
  • Planning
  • Decision making
41
Q

What appears to have quite a strong contribution to the development of schizophrenia?

A

Genetics

42
Q

Once schizophrenia has been diagnosed, what are the four main outcomes for patients?

A

1 – illness resolves completely, with or without treatment and never returns (10-20%)
2 – illness recurs repeatedly with full recovery between episodes (30-35%)
3 – illness recurs repeatedly with incomplete recovery and a persistent defective state develops, becoming more profound with each successive relapse (30-35%)
4 – illness pursues down a downhill course from the beginning (10-20%)

NOTE: most cases are relapsing and remitting

43
Q

Describe the involvement of dopamine in schizophrenia.

A

Positive symptoms – results from excessive dopamine transmission in the mesolimbic and striatal region (D2-mediated)

Negative symptoms – results from dopamine deficit in the pre-frontal region (D1-mediated)

44
Q

What evidence has arisen that supports the hypothesis of dopamine involvement in schizophrenia?

A

Dopamine agonists can induce various psychotic reactions

Typical antipsychotics are dopamine receptor antagonists (blocking D2 receptors)

45
Q

Describe the involvement of glutamate in schizophrenia.

A

NMDA is a glutamate receptor
Glutamate exerts an excitatory influence over the GABA-ergic striatal neurones and dopamine exerts an inhibitory influence
These GABA-ergic striatal neurones project to the thalamus and constitute a sensory ‘gate’
Too little glutamate or too much dopamine disables this gate, allowing uninhibited sensory input to reach the cortex

NOTE: you find reduced glutamate concentration and reduced glutamate receptors in post-mortem schizophrenic brains. Also NMDA receptor antagonists can produce psychotic symptoms

46
Q

What is the most robust gene associated with schizophrenia?

A

Neuregulin-1

47
Q

What are all the susceptibility genes for schizophrenia associated with?

A

Dopamine and glutamate neurotransmission

48
Q

What type of drug are all neuroleptics?

A

Dopamine receptor antagonists (D2 receptors)

NOTE: most neuroleptics block other receptors

49
Q

Which symptoms do neuroleptic drugs treat?

A

Positive symptoms ONLY (D2 mediated)

50
Q

What are the initial effects of neuroleptic drugs?

A

Initial increase in dopamine synthesis and neuronal activity – this declines with time

51
Q

What are the extrapyramidal side effects of antipsychotics caused by?

A

Blockade of dopamine receptors in the nigrostriatal system can induce
Parkinson-like side effects

52
Q

What are the two main extra-pyramidal side effects?

A

Acute Dystonia

  • Involuntary movements
  • Muscle spasm, protruding tongue, fixed upward gaze, neck spasm etc.
  • Often accompanied by Parkinson’s like features
  • Occur in the FIRST FEW WEEKS and often decline with ongoing therapy
  • Reversible with withdrawal of the drug or anti-cholinergics

Tardive Dyskinesias

  • Involuntary movements
  • Involving the face and tongue, but also trunk and limbs
  • Occur in 20% of patients after SEVERAL MONTHS /YEARS of therapy
  • Made WORSE by drug withdrawal or anti-cholinergics
53
Q

What are the unwanted effects of antipsychotics?

A

Endocrine effects – loss of inhibition of prolactin secretion leads to hyperprolactinaemia (can lead to breast swelling and sometimes lactation)

Blocking alpha-adrenoceptors – postural hypotension

Blocking 5-HT receptors – weight gain

Blockade of muscarinic receptors – typical anti-muscarinic effects e.g. blurring of vision, increased intra-ocular pressure, dry mouth, constipation, urinary retention

54
Q

Describe Chlorpromazine as an anti-psychotic

A

Typical (1st Gen)

D2 antagonism/H1 antagonism/ACh antagonism
Low incidence of Extrapyramidal side effects (EPS) but high Anti-muscarinic effects

55
Q

Describe Haloperidol as an anti-psychotic

A

Typical (1st Gen)

50x more potent D2 antagonism than chlorpromazine, But high EPS

56
Q

Describe Clozapine as an anti-psychotic

A

Atypical (2nd Gen)

5-HT2A antagonist
MOST EFFECTIVE NEUROLEPTIC – Treats negative side effects to an extent (only licensed drug that does so)

Bad side effects – Can cause neutropenia, agranulocytosis, myocarditis and weight gain

57
Q

Describe Risperidone as an anti-psychotic

A

Atypical (2nd Gen)
5-HT and D2 Antagonist
EPS side effects/Hyperprolactinaemia

58
Q

Describe Quetiapine as an anti-psychotic

A

Atypical (2nd Gen)
H1 antagonist
Low EPS side effects

59
Q

Describe Aripiprazole as an anti-psychotic

A

Atypical (2nd Gen)

Partial agonist D2 and 5-HT1a (May be able to increase Mesocortical and reduce Mesolimbic)
But no more efficacious

Reduced hyperprolactinaemia and weight gain compared to other anti-psychotics